CSFM de expansión de células T TS™ OpTmizer™, formato de botella

Citas y referencias (7)

Gibco™

CSFM de expansión de células T TS™ OpTmizer™, formato de botella

El SFM de expansión de células T GIBCO OpTmizer™ CTS™ se ha desarrollado para el crecimiento y la expansión deMás información

Número de catálogo	Cantidad
A1048501	1 frasco

Número de catálogo A1048501

Precio (MXN)

Cantidad:

1 frasco

El SFM de expansión de células T GIBCO OpTmizer™ CTS™ se ha desarrollado para el crecimiento y la expansión de linfocitos T humanos. El medio de expansión de células T OpTmizer™ CTS™ es un completo medio 1X sin suero ni xenógenos compuesto de medio basal de expansión de células T OpTmizer™ (botella de 1 l) y suplemento de expansión de células T OpTmizer™ (26 ml), que se mezclan antes de usar.

• Mantiene un fenotipo y una función similares (p. ej., perfil de secreción de citocinas) de células T cultivadas y activadas policlonalmente, como se observa para el medio sumplementado de suero
•Rendimiento constante en el apoyo a la expansión de células T
• Admite cultivo de células T de alta densidad (p. ej., > 3x10⁶ CD3+ células T/ml) en cultivo estático

Con SFM de expansión de células T OpTmizer™, ofrecemos a las comunidades de investigación clínica y básica una nueva herramienta para mejorar su éxito en el crecimiento de células T humanas. Está especialmente formulado para permitir un crecimiento celular y una viabilidad excelentes, menos variabilidad y resultados más uniformes, así como facilitar la transición de la investigación a las aplicaciones clínicas.

Ventajas para el flujo de trabajo:
• Minimización de la necesidad de manejar la compra, el almacenamiento, la calificación del suero y, por lo tanto, reducir la variabilidad y los costes
• Expansión de células T más rápida, lo que reduce el tiempo de ciclo y mejora la productividad
• Medio completo sin suero ni xenógenos, lo que permite una transición perfecta de la investigación a las aplicaciones clínicas y minimiza la carga de trabajo regulatorio

Especificaciones

Tipo de célulaCélulas T

Entorno de cultivoCO₂

Nivel de endotoxinasMuy bajo

Antibióticos incluidosSin antibióticos

Sales inorgánicasCalcio o magnesio

Línea de productosCTS, OpTmizer

Tipo de productoMedio sin suero (SFM) de expansión celular

Grado de pureza o calidadCalidad para investigación

Cantidad1 frasco

ClasificaciónSin suero, ni xenógenos

Culture TypeCultivos celulares en suspensión

FormularioLíquido

Serum LevelSin suero

EsterilidadEstéril

Con aditivosÁcido 4-(2-hidroxietil)piperazin-1-iletanosulfónico (HEPES), Rojo de fenol, Piruvato sódico, Bicarbonato sódico

Sin aditivosSin glutamina

Unit SizeEach

Contenido y almacenamiento

Medio basal de expansión de células T OpTmizer™ (frasco de 1 x 1000 ml): Almacenar de 2 a 8 °C. Proteja el producto de la luz.

Suplemento de expansión de células T de OpTmizer™ (1 x 26 ml): Almacenar en un lugar oscuro a una temperatura de 2 a 8 °C.

Preguntas frecuentes

What is CTS?

The Gibco Cell Therapy Systems (CTS) portfolio of cell and gene therapy products are GMP manufactured, safety tested, and backed by regulatory documentation to support your transition from discovery through clinical and commercial manufacturing. Through our CTS solutions, we are committed to helping customers streamline therapeutic development, minimize risk, and ease the burden on their quality systems. Learn more here.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Do I need to order additional components with the CTS OpTmizer T Cell Expansion SFM (Cat. Nos. A1048501, A1048502, A1048503)?

The CTS OpTmizer T Cell Expansion SFM (Cat. Nos. A1048501, A1048502, A1048503) kit comes with OpTmizer T Cell Expansion Basal Medium and OpTmizer T Cell Expansion Supplement, which are mixed together prior to use. Depending on your protocol you may need to purchase T cell growth factors such as IL-2 (Cat. No. PHC0023) and L-glutamine (Cat. No. 25030) to form a complete medium. To boost growth of human T cells, human AB serum can be added. If desired, antibiotics such as Gentamicin (Cat. No. 15750), can also be added.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Will CTS OpTmizer T Cell Expansion SFM (Cat. No. A1048501, A1048502, A1048503) work with all types of T cells?

CTS OpTmizer T Cell Expansion SFM (Cat. No. A1048501, A1048502, A1048503) has been demonstrated to be effective for the ex vivo expansion of human CD3 T cells, including polyclonal T cell populations, antigen-specific T cells, tumor-infiltrating lymphocytes (TIL), cord blood T cells, regulatory T cells, T cells from HIV-infected donors, gene-modified T cells (both lenti- and MLV-based vectors), including cells of both the CD4+ and CD8+ phenotype.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Can CTS OpTmizer T Cell Expansion SFM (Cat. Nos. A1048501, A1048502, A1048503) be used for animal T cell cultures other than human?

CTS OpTmizer T Cell Expansion SFM (Cat. No. A1048501, A1048502, A1048503) has only been tested on human T cells.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

Is there a difference in formulation of the CTS OpTmizer T Cell Expansion SFM between the bottle and bag packaging formats?

The bottle and bag packaging formats of the medium have the same formulation.

Find additional tips, troubleshooting help, and resources within our Cell Culture Support Center.

View all CSFM de expansión de células T TS™ OpTmizer™, formato de botella FAQs

Citations & References (7)

Citations & References

Abstract

Performance of serum-supplemented and serum-free media in IFNgamma Elispot Assays for human T cells.

Authors:Janetzki S, Price L, Britten CM, van der Burg SH, Caterini J, Currier JR, Ferrari G, Gouttefangeas C, Hayes P, Kaempgen E, Lennerz V, Nihlmark K, Souza V, Hoos A,

Journal:Cancer Immunol Immunother

PubMed ID:19894047

'The choice of serum for supplementation of media for T cell assays and in particular, Elispot has been a major challenge for assay performance, standardization, optimization, and reproducibility. The Assay Working Group of the Cancer Vaccine Consortium (CVC-CRI) has recently identified the choice of serum to be the leading cause ... More

Impact of culture medium on the expansion of T cells for immunotherapy.

Authors:Sato K, Kondo M, Sakuta K, Hosoi A, Noji S, Sugiura M, Yoshida Y, Kakimi K,

Journal:Cytotherapy

PubMed ID:19903105

'BACKGROUND AIMS: Encouraging evidence of clinical benefits from cancer immunotherapy is beginning to accumulate in several clinical trials. Cancer immunotherapy is based on two main methods, active vaccination and cell-transfer therapy. The ex vivo expansion of T cells is required to monitor vaccine-induced antigen-specific T cells or prepare large numbers ... More

Ex vivo expansion of human T cells for adoptive immunotherapy using the novel Xeno-free CTS Immune Cell Serum Replacement.

Authors:Smith C, Økern G, Rehan S, Beagley L, Lee SK, Aarvak T, Schjetne KW, Khanna R

Journal:

PubMed ID:25671129

The manufacture of clinical grade cellular products for adoptive immunotherapy requires ex vivo culture and expansion of human T cells. One of the key components in manufacturing of T cell therapies is human serum (HS) or fetal bovine serum (FBS), which can potentially expose immunotherapy recipient to adventitious infectious pathogens ... More

Bioengineering and serum free expansion of blood-derived ?d T cells.

Authors:Sutton KS, Dasgupta A, McCarty D, Doering CB, Spencer HT

Journal:Cytotherapy

PubMed ID:27260209

'Cellular immunotherapy relies on several highly variable patient-specific parameters, such as (i) cell number before and after expansion, (ii) targeting of cells to tumors, (iii) cell survival and function after infusion, and (iv) on- and off-target adverse events. Cellular approaches such as the specific expansion of ?d T cells as ... More

A Rapid Cell Expansion Process for Production of Engineered Autologous CAR-T Cell Therapies.

Authors:Lu TL, Pugach O, Somerville R, Rosenberg SA, Kochendefer JN, Better M, Feldman SA

Journal:Hum Gene Ther Methods

PubMed ID:27897048

The treatment of B-cell malignancies by adoptive cell transfer (ACT) of anti-CD19 chimeric antigen receptor T cells (CD19 CAR-T) has proven to be a highly successful therapeutic modality in several clinical trials.(1-6) The anti-CD19 CAR-T cell production method used to support initial trials relied on numerous manual, open process steps, ... More

View all CSFM de expansión de células T TS™ OpTmizer™, formato de botella citations